Skip to main content

OPEN-LABEL, RANDOMISED, COMPARATIVE PHASE IV PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A RILPIVIRINE-BASED ANTIRETROVIRAL TREATMENT REGIMEN IN HIV-INFECTED PATIENTS WITH METABOLIC LIVER DISEASE WHO MAINTAIN AN UNDETECTABLE HIV VIRAL LOAD

OPEN-LABEL, RANDOMISED, COMPARATIVE PHASE IV PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A RILPIVIRINE-BASED ANTIRETROVIRAL TREATMENT REGIMEN IN HIV-INFECTED PATIENTS WITH METABOLIC LIVER DISEASE WHO MAINTAIN AN UNDETECTABLE HIV VIRAL LOAD
  • ACRONYM: MAFALDA
  • FSG CODE: GESIDA 12422
  • COORDINATOR: MARÍA LUISA MONTES
  • COORDINATOR’S HOSPITAL: HOSPITAL UNIVERSITARIO LA PAZ, MADRID 
  • APPROVAL DATE: 11-FEB.-2023
  • PROTOCOL STATUS: FOLLOWING
  • CEIC-S APPROVAL: YES
  • AEMYPS APPROVAL: YES
  • ENROLED PATIENTS: 20
  • TOTAL NUMBER OF PATIENTS TO INCLUDE: 75